Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO 2019 Expert Video Report in Upper Gastrointestinal Cancers

Reporting from ESMO 2019 Congress, Florian Lordick comments on results from the ATTRACTION-3 positive study with immune checkpoint inhibitor in second-line treatment for metastatic oesophageal squamous cancer that show clinically relevant benefit, although it is necessary to see if the results will translate also into non-Asian populations. He also discusses 2 presentations from the KEYNOTE-062 study with non-inferior health-related quality-of-life data and a biomarker analysis in first-line treatment for advanced gastric cancer - while no benefit was observed with immunotherapy alone in the overall study population, there was a clear benefit in patients with MSI-high tumours which justifies upfront testing and a specific treatment approach.

Abstracts:

  • LBA11: Nivolumab Versus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC): The Phase 3 ATTRACTION-3 Study
  • LBA44: Pembrolizumab With or Without Chemotherapy vs Chemotherapy in Patients With Advanced G/GEJ Cancer (GC) Including Outcomes According to Microsatellite Instability-High (MSI-H) Status in KEYNOTE-062
  • LBA45: Health-Related Quality of Life (HRQoL) Impact of Pembrolizumab (P) Versus Chemotherapy (C) as First-Line (1L) Treatment in PD-L1–Positive Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings